Twenty-seven days after our first product was launched, a young girl used it to save her own life. Each one of us at kaléo can tell you exactly where he or she was when they heard the wonderful news. As a company founded by patients, we are passionate about developing innovative solutions for serious and life-threatening medical conditions.
That is why we are joining forces with the Clinton Health Matters Initiative (CHMI) to help achieve the critical goal of cutting prescription drug-related deaths in half and saving approximately 10,000 lives.
The numbers are tragic. Forty-four people die from prescription opioids every day in the United States, most occurring outside of medical settings and are witnessed by friends or family. The victims are not just adults. In fact, each year, more than 3,300 children age 5 and under are rushed to emergency rooms due to accidental opioid exposure. The crisis has become so great that the U.S. Centers for Disease Control declared deaths from prescription opioid overdose to be a national public health epidemic.
When an overdose occurs, seconds count. As a result of an opioid overdose, a person’s breathing will become slow or shallow or even stop, which is the most serious adverse effect of opioids because it can be life-threatening. Without quick intervention, severe clinical consequences may occur within minutes; lack of oxygen can lead to brain injury in as little as 4 minutes.
This national strategic partnership between kaléo and the Clinton Health Matters Initiative is focused on a common goal – to put a potentially life-saving drug that can reverse opioid overdoses in the hands of people who can intervene quickly. Together, we are committed to stopping this national crisis in its tracks.
From our founding, we have been dedicated to designing products suited to meet the unique needs of each user. Kaléo seeks to turn “I can’t” into “I can” by putting the power back into patients’ hands. This partnership with the Clinton Health Matters Initiative makes that dream a reality.
Read more about how our partnership with kaléo lowers the cost of this life-saving treatment in The New York Times.